Earning 52.47 million yuan daily while distributing 5.7 billion yuan in dividends! Does WuXi AppTec provide shareholders with full and adequate returns?

Ask AI · How will WuXi AppTec TIDES achieve a 96% explosive growth?

Produced by|China Research Network

Reviewed by|Li Xiaoyan

On the evening of March 22, A-share “most profitable pharmaceutical company” WuXi AppTec (603259.SH/02359.HK) released its 2025 full-year results report, delivering a record-best answer with both revenue and net profit rising: full-year operating revenue reached RMB 8B, up 15.84% year over year; net profit attributable to shareholders of listed companies was RMB 45.46B, up 102.65% year over year, translating into average daily earnings of about RMB 52.47 million. At the same time, the company announced a major dividend plan: in 2025, it plans to distribute RMB 19.15B in cash; combined with the RMB 1.0 billion interim dividend plan in 2026, the total dividends for the year will reach RMB 5.71 billion, setting a new historical high. Supported by strong performance and its “reservoir” of outstanding orders of RMB 58.0 billion, WuXi AppTec is confident in growth for 2026, expecting full-year overall revenue of RMB 51.3 billion–53.0 billion, with revenue from continuing operations growing 18%–22% year over year.

In 2025, WuXi AppTec’s net profit doubled year over year, far exceeding market expectations, becoming its most impressive year since going public. Behind this performance are three overlapping drivers: growth in its core business, optimization of operating efficiency, and gains from asset disposals.

From the perspective of core operations, the company focuses on its CRDMO (chemical pharmaceutical R&D and manufacturing services) core strategy, and its business structure has continued to improve. In 2025, revenue from continuing operations was RMB 43.42 billion, up 21.4% year over year, higher than the overall revenue growth rate, highlighting the quality of the core business. As the growth engine, its chemical segment contributed revenue of RMB 4.71B, up 25.52%; among this, the TIDES business (oligonucleotides and peptides) performed particularly strongly, with revenue reaching RMB 11.37 billion, up 96.0% year over year. Its outstanding orders increased 20.2% year over year, becoming the core new engine driving performance. This explosive growth stems from a revolutionary breakthrough in the GLP-1 diabetes and weight-loss field, driving a surge in global demand for peptide drugs, further generating contracted manufacturing orders—and also demonstrating the company’s precise positioning in a cutting-edge track.

Continued improvement in operating efficiency further amplifies profitability. The company improved production processes and increased utilization rates, with the proportion of late-stage clinical and commercial projects increasing continuously, driving adjusted non-IFRS gross margin up to 48.2%. Meanwhile, the company’s cost control results were significant: operating costs increased only 3.64% year over year, far lower than the revenue growth rate, further thickening profits.

In addition, gains from asset disposals became an important supplementary source of profit growth. During the reporting period, the company sold part of its stake in the associate WuXi HeLian and divested part of its business, realizing investment gains of RMB 36.47B, up 13.21 times year over year, significantly enhancing overall profit levels. It is worth noting that even after excluding the impact of non-recurring profit and loss, the company’s net profit excluding non-recurring profit and loss still reached RMB 8.59B, up 32.56% year over year, demonstrating the resilient growth capability of its core operations.

WuXi AppTec’s global business layout shows a differentiated pattern of “core markets steady, emerging markets growing.” The U.S. market, as the largest revenue source, has become the ballast for performance growth. In 2025, revenue from continuing operations from the U.S. market reached RMB 31.25 billion, up 34.3% year over year, with a growth rate significantly higher than the overall level, further solidifying its leading position in the global pharmaceutical R&D services sector.

By contrast, revenue from Europe and China declined: RMB 4.82 billion (down 4.0% year over year) and RMB 5.47 billion (down 3.5% year over year), respectively; revenue from Japan, South Korea, and other regions was RMB 1.88 billion, up 4.1% year over year. The divergence across regions is driven not only by adjustments to global geopolitical and cross-border regulatory policies, but also by differences in the pace of business expansion in different regional markets.

However, the large pool of outstanding orders provides solid protection for future performance growth. By the end of 2025, WuXi AppTec’s outstanding orders from continuing operations were RMB 58.0 billion, up 28.8% year over year; among this, approximately RMB 422.0 billion is expected to be recognized as revenue in 2026, basically covering the full-year revenue target and providing a high level of certainty for performance growth in 2026. Chairman Li Ge stated that the outstanding orders fully reflect the unique advantages of the company’s CRDMO business model and the trust of global customers, laying the foundation for rapid business growth in 2026.

Along with strong performance growth, WuXi AppTec has continued to increase its returns to shareholders, fulfilling its commitment to “reward investors.” According to the annual report, the company’s 2025 profit distribution plan is to pay cash dividends of RMB 15.79 per 10 shares (including tax), for a total cash dividend of RMB 13.24B. Adding the RMB 4.71B interim dividend and the RMB 1.03B special dividend already implemented earlier in 2025, the total cash dividends for 2025 reach RMB 1.01B. In addition, the company plans to repurchase and cancel shares of RMB 2.0 billion; the total return to shareholders is RMB 6.76B, accounting for 45.72% of this year’s net profit.

More noteworthy is that the company has clearly defined its 2026 dividend plan: it will maintain the RMB 1.0 billion interim dividend arrangement in 2026, and combined with the 2025 dividends, the total cash dividends in 2026 will reach RMB 5.71 billion, setting another historical high. This move not only demonstrates the company’s confidence in its own cash flows and future profitability, but also provides investors with stable dividend expectations.

For its development in 2026, WuXi AppTec has set clear goals: total revenue of RMB 51.3 billion–53.0 billion, continuing-operations revenue growing 18%–22% year over year, adjusted free cash flow of RMB 10.5 billion–11.5 billion, and capital expenditures controlled at RMB 6.5 billion–7.5 billion. The company said it will focus on its CRDMO core strategy, accelerate the development of global capabilities and capacity deployment, continuously optimize production and operating efficiency, and consolidate its leading position in the industry.

Despite outstanding performance in 2025, WuXi AppTec still faces challenges and needs to take a rational view of the sustainability of its growth.

First, the risk of volatility in regional markets. Revenue from Europe and China declined, reflecting pressure on the company’s expansion in major regional markets; if geopolitical tensions and regulatory policies continue to tighten, it may further affect business execution. Second, the risk of currency exchange rate fluctuations. The company’s revenue is mainly settled in U.S. dollars; in 2025, the depreciation of the U.S. dollar against the RMB resulted in large foreign exchange losses. If the RMB continues to appreciate, it will have an adverse impact on profitability.

Furthermore, the risk of intensifying industry competition. Competition in the global CXO industry is getting increasingly fierce; competitors are continuously increasing efforts in technological R&D and market deployment. If the company cannot continuously strengthen its technological advantages and improve service quality, it may face risks such as erosion of market share and intensified price competition. In addition, the uncertainty in returns on newly built capacity. In 2026, the company plans to increase capital expenditures to push capacity construction; if the construction of new capacity is delayed, regulatory approvals do not meet expectations, or market demand changes, investment returns may fall below expectations, affecting financial performance.

Overall, in 2025, WuXi AppTec delivered an answer that set new historical highs thanks to strong core business growth, efficient operating management, and generous shareholder returns. The RMB 58.0 billion pool of outstanding orders also provides solid assurance for growth in 2026. As a global leader in the CRDMO industry, the company has clear advantages in technological capabilities, global footprint, and customer resources. It can align with the global pharma outsourcing trend and benefit from the continued growth in demand for innovative drug R&D.

Although it faces multiple challenges including regional market volatility, currency exchange rate competition, and regulatory policy changes, the company is expected to gradually mitigate risks and achieve steady growth by focusing on its core strategy, optimizing its business structure, and improving operating efficiency. In 2026, with new businesses such as TIDES continuing to ramp up, global capacity gradually being released, and the continued implementation of its dividend plans, WuXi AppTec is expected to further consolidate its position as an industry leader and create greater value for investors.